Guggenheim Capital LLC cut its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 23.9% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 58,778 shares of the medical equipment provider’s stock after selling 18,429 shares during the period. Guggenheim Capital LLC’s holdings in Hologic were worth $2,063,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also bought and sold shares of the company. Sunbelt Securities Inc. purchased a new position in shares of Hologic during the fourth quarter valued at approximately $6,526,000. Ancora Advisors LLC purchased a new position in shares of Hologic during the fourth quarter valued at approximately $39,000. Signaturefd LLC increased its stake in shares of Hologic by 67.4% during the first quarter. Signaturefd LLC now owns 792 shares of the medical equipment provider’s stock valued at $28,000 after buying an additional 319 shares during the period. Total Clarity Wealth Management Inc. purchased a new position in shares of Hologic during the fourth quarter valued at approximately $45,000. Finally, CWM LLC increased its stake in shares of Hologic by 63.4% during the first quarter. CWM LLC now owns 910 shares of the medical equipment provider’s stock valued at $32,000 after buying an additional 353 shares during the period. 92.45% of the stock is currently owned by hedge funds and other institutional investors.

HOLX has been the topic of several research analyst reports. Wells Fargo & Co boosted their target price on Hologic from $48.00 to $60.00 and gave the company an “overweight” rating in a research note on Thursday, April 30th. UBS Group reduced their price target on Hologic from $58.00 to $52.00 and set a “neutral” rating on the stock in a research note on Tuesday, April 28th. Zacks Investment Research cut Hologic from a “hold” rating to a “sell” rating and set a $52.00 price target on the stock. in a research note on Tuesday, April 28th. Raymond James raised Hologic from a “market perform” rating to an “outperform” rating and set a $62.00 price target on the stock in a research note on Wednesday, June 3rd. Finally, Cowen raised Hologic from a “market perform” rating to an “outperform” rating and set a $64.00 price target on the stock in a research note on Tuesday. One research analyst has rated the stock with a sell rating, seven have given a hold rating and twelve have issued a buy rating to the company’s stock. The company presently has an average rating of “Buy” and a consensus price target of $57.06.

NASDAQ HOLX opened at $57.86 on Friday. Hologic, Inc. has a 12 month low of $26.49 and a 12 month high of $58.72. The stock has a market cap of $14.94 billion, a P/E ratio of 25.27, a P/E/G ratio of 3.61 and a beta of 1.47. The stock’s fifty day moving average price is $53.16 and its 200-day moving average price is $48.97. The company has a current ratio of 1.31, a quick ratio of 1.04 and a debt-to-equity ratio of 1.32.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, April 29th. The medical equipment provider reported $0.57 EPS for the quarter, hitting analysts’ consensus estimates of $0.57. Hologic had a return on equity of 30.49% and a net margin of 18.53%. The firm had revenue of $756.10 million for the quarter, compared to analysts’ expectations of $756.10 million. During the same period in the prior year, the firm posted $0.58 earnings per share. As a group, analysts forecast that Hologic, Inc. will post 2.28 earnings per share for the current fiscal year.

In other news, CEO Stephen P. Macmillan sold 190,996 shares of the company’s stock in a transaction on Wednesday, May 13th. The stock was sold at an average price of $50.97, for a total transaction of $9,735,066.12. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, General Counsel John M. Griffin sold 4,906 shares of the company’s stock in a transaction on Tuesday, April 28th. The shares were sold at an average price of $50.00, for a total value of $245,300.00. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 248,838 shares of company stock worth $12,752,550. Corporate insiders own 1.00% of the company’s stock.

Hologic Profile

Hologic, Inc, a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health.

Further Reading: Why does the United States have a lingering trade deficit?

Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).

Institutional Ownership by Quarter for Hologic (NASDAQ:HOLX)

Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.